A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants

Launched by ELI LILLY AND COMPANY · Jul 17, 2023

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male and female participants who are overtly healthy as determined by medical history, physical examination, and other screening procedures
• • A minimum body weight of 45 kilograms and body mass index (BMI) between 18.0 and 32.0 kilograms per meter squared (kg/m²), inclusive, at screening
• • Have blood pressure, pulse rate, blood and urine laboratory test results that are acceptable for the study
• • Males who agree to use highly effective/effective methods of contraception and women not of childbearing potential
• Exclusion Criteria:
• • Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, of constituting a risk when taking the study intervention, or of interfering with the interpretation of data
• • Have a history of allergy to monoclonal antibody therapy or to the excipients in the drug formulation, or have clinically significant intolerance to topical corticosteroids, or a history of severe posttreatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis).
• * Have a diagnosis or history of malignant disease within 5 years prior to screening, with the following exceptions:
• • 1. basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years
• • 2. cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to screening.
• • Are immunocompromised.
• • Have known hypogammaglobulinemia
• • Have a current or recent acute, active infection. For at least 30 days before screening and up to the baseline visit, participants must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment.
• * Have had any of the following types of infection within 3 months prior to the screening visit or develops any of these infections before the baseline visit:
• • 1. serious (requiring hospitalization, or IV or equivalent oral antibiotic treatment, or both)
• • 2. opportunistic (as defined in Winthrop et al. 2015)
• • 3. chronic (duration of symptoms, signs, and/or treatment of 6 weeks or longer)
• • 4. recurring (including, but not limited to, herpes simplex, herpes zoster, recurring cellulitis, chronic osteomyelitis).
• • Have active TB.
• • Have or have had latent tuberculosis infection that has not been treated with a complete course of appropriate therapy as defined by the World Health Organization and the United States Centers for Disease Control and Prevention, unless such treatment is underway.
• • Have a current infection with HBV (that is, positive for hepatitis B surface antigen and/or polymerase chain reaction positive for HBV DNA).
• • Have a current infection with HCV (that is, positive for HCV RNA).
• • Have HIV infection.
• • Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing.
• • Have received any live vaccine (that is, live attenuated) within less than 4 weeks before screening or intend to receive a live vaccine during the study, or within 5 half-lives (8 weeks) after receiving the last dose of study intervention, whichever is longer. Note: The following are not considered live vaccines: RNA vaccines, vaccines with inactive viral elements, and/or nonreplicating viral vector vaccines.
• • Have received a bacille Calmette-Guerin vaccination or treatment within less than 4 weeks before screening or intend to receive bacille Calmette-Guerin vaccination or treatment during the study, or within 5 half-lives (8 weeks) after receiving the last dose of study intervention, whichever is longer.